Key result
Molecular imaging of the cardiac extracellular matrix may help understand pathology, evaluate the impact of novel therapies, and predict the extent of extracellular matrix expansion.
Molecular imaging of the cardiac extracellular matrix offers a potential clinical tool to understand pathology, evaluate novel therapies, and predict ECM expansion for personalized treatment.
Answers are grounded in this paper and cite their sources.
May advance ECM imaging research; leaves open clinical adoption pending prospective validation.
In almost all cardiac diseases, an increase in extracellular matrix (ECM) deposition or fibrosis occurs, mostly consisting of collagen I. Whereas replacement fibrosis follows cardiomyocyte loss in myocardial infarction, reactive fibrosis is triggered by myocardial stress or inflammatory mediators and often results in ventricular stiffening, functional deterioration, and development of heart failure. Given the importance of ECM deposition in cardiac disease, ECM imaging could be a valuable clinical tool. Molecular imaging of ECM may help understand pathology, evaluate impact of novel therapy, and may eventually find a role in predicting the extent of ECM expansion and development of personalized treatment. In the current review, we provide an overview of ECM imaging including the assessment of ECM volume and molecular targeting of key players involved in ECM deposition and degradation. The targets comprise myofibroblasts, intracardiac renin-angiotensin axis, matrix metalloproteinases, and matricellular proteins.
No takes yet. Share an insight, caveat, or question.
Haas et al. (2014) conducted a review in Cardiac diseases. Molecular imaging of the cardiac extracellular matrix was evaluated. Molecular imaging of the cardiac extracellular matrix may help understand pathology, evaluate the impact of novel therapies, and predict the extent of extracellular matrix expansion.
Synapse has enriched 10 related papers. Consider them for comparative context: